<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223206</url>
  </required_header>
  <id_info>
    <org_study_id>K2DTD75_ALTISnefro</org_study_id>
    <nct_id>NCT04223206</nct_id>
  </id_info>
  <brief_title>Innovative Functional Food Based on Apulian Lens Culinaris for Contrasting Sarcopenia in Dialysis Patients</brief_title>
  <acronym>ALTIS</acronym>
  <official_title>K2DTD75 - ALTIS &quot;Alimento Funzionale a Base di Lens Culinaris Tipico Del Territorio Pugliese ed Innovativo Per la Salute&quot; - Regione Puglia &quot;INNONETWORK 2017&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Consorziale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università degli Studi di Bari Aldo Moro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Consorziale</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the pilot study is to validate the clinical use of a dietary supplement for
      contrasting sarcopenia in dialysis patients.

      The study aims at evaluating the effects of a nutritional supplement, consisting of flour
      from Lens culinaris of Altamura IGP, pea proteins and vitamins (A, B12, D, E) by achieving
      the following objectives:

        -  Reduction of sarcopenia conditions, through improvement of nutritional and
           anthropometrical levels

        -  Decrease of the serum levels of microbiota-derived uremic toxins

        -  Reduction of intestinal permeability and inflammatory markers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of muscle mass</measure>
    <time_frame>3 months</time_frame>
    <description>Change of muscle mass by bioelectrical impedance assessment (BIA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of sarcopenia conditions</measure>
    <time_frame>3 months</time_frame>
    <description>Change of sarcopenia assessed by the European Working Group on Sarcopenia in Older People (EWGSOP) guidelines through the SARC-F (Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls) questionnaire. The SARC-F scale scores range from 0 to 10 (i.e. 0-2 points for each item; 0=best to 10=worst) and represents no sarcopenia (0-3) and sarcopenia (4-10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mini Nutritional Assessment (MNA) score</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of MNA questionnaire (12-14 points, normal nutritional status; 8-11 points, at risk of malnutrition; 0-7, malnourished)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of anthropometric parameter</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of the arm circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of body mass index (BMI)</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of BMI (kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of gastrointestinal symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Change of gastrointestinal symptoms assessed by Gastrointestinal Symptom Rating Scale (GSRS) questionnaire (15 items scored 1-7 each, 1 representing the best and 7 the worse outcome for each item).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of stool type</measure>
    <time_frame>3 months</time_frame>
    <description>Change of stool type evaluated by BRISTOL Stool Scale (range 1-7, lower and higher values representing worse outcome, middle values representing better outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum concentration of IS and pCS</measure>
    <time_frame>3 months</time_frame>
    <description>Change of free and total indoxyl sulfate (IS) and p-cresyl sulfate (pCS) serum concentrations (μg/mL) assessed by liquid chromatography/mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum concentration of inflammatory markers</measure>
    <time_frame>3 months</time_frame>
    <description>Change of serum concentrations of interleukins: IL-6, TNF-α, IL-1, IL-8, IL-10 (pg/mL) evaluated by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood glucose level</measure>
    <time_frame>3 months</time_frame>
    <description>Change of glycemia concentration (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of insulin levels</measure>
    <time_frame>3 months</time_frame>
    <description>Change of insulin concentration (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of endocrine parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Change of C-peptide, growth hormone (GH), insulin-like growth factor 1 (IGF-1), testosterone concentration (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum concentration of D-lactate</measure>
    <time_frame>3 months</time_frame>
    <description>Change of D-lactate serum concentration (uM)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>3 months</time_frame>
    <description>Change of the relative abundance (%) of Operational Taxonomic Units (OTUs) of Firmicutes, Bacteroidetes,Proteobacteria, Verrucomicrobia, Actinobacteria, Synergistetes, Cyanobacteria, Euryarchaeota, Chloroflexi, Nitrospirae, Tenericutes, Fusobacteria, Thermotogae, Acidobacteria evaluated by fecal bacterial DNA genome sequencing.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Hemodialysis with sarcopenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 HD patients, affected by sarcopenia will a undergo 3-months supplementation with NATURLENS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 HD patients, affected by sarcopenia will be followed for 3 months without any supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NATURLENS</intervention_name>
    <description>Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water</description>
    <arm_group_label>Hemodialysis with sarcopenia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt; 60 years old

          -  omnivore controlled normocaloric diet (30 Kcal/kg ideal weight)

          -  patients with chronic kidney disease (CKD) and routine hemodialysis or peritoneal
             dialysis

          -  patients with primary sarcopenia identified with score ≥ 4 at SARC-F Questionnaire

          -  informed consent signed

        Exclusion Criteria:

          -  participation to another clinical trial

          -  limb removal by amputation

          -  altered blood sugar level (HbA1c&gt;8.0%) or type I diabetes mellitus

          -  neoplastic events in the last 5 years

          -  gut, systemic or autoimmune chronic inflammatory pathologies

          -  use of antibiotics or probiotics up to 30 days prior to recruitment

          -  life expectancy of less than one year

          -  treatment with corticosteroids or immunosuppressive drugs (excluded prednisone at dose
             &lt;5 mg at day)

          -  positivity to hepatitis B and C virus, HIV1/2 and syphilis

          -  oxygen saturation in the blood at rest &lt;93%

          -  alcohol or drug abuse in the last 3 years

          -  clinically important alterations of the following laboratory parameters: hemoglobin
             &lt;9.0 g / dL, white blood cells &lt;2.500 / μl, platelet count &lt;100.000 / μl, AST and ALT&gt;
             3 times the upper limit of the norm, coagulopathy (INR&gt; 1.3 ) not due to a reversible
             cause (eg Warfarin and / or factor Xa inhibitors)

          -  uncontrolled hypertension (resting systolic blood pressure&gt; 180 mmHg or diastolic
             blood pressure&gt; 110 mmHg)

          -  unstable angina pectoris, severe peripheral artery disease, coronary bypass surgery,
             angioplasty or acute major cardiocirculatory diseases in the previous 3 months

          -  definite congestive heart failure class III or IV (NYHS) or ejection fraction &lt;25%

          -  severe pulmonary dysfunction: acute exacerbation of chronic obstructive pulmonary
             disease in phase III or IV (Gold classification) and / or PaO2 levels &lt;60 mmHg

          -  significant intestinal malabsorption due to partial ileal bypass or other causes

          -  score ≤ 24 at the Mini Mental State Examination (MMSE) or presence of cognitive or
             linguistic limits that prohibit informed consent or possible elements of study

          -  diagnosis of disabling neurological disorder, including Parkinson's disease,
             amyotrophic lateral sclerosis, multiple sclerosis, cerebrovascular accident with
             residual deficits (for example, muscle weakness or gait disorder), dementia or any
             psychiatric condition that reduces protocol compliance

          -  have a history or evidence of any condition, therapy, laboratory abnormality or other
             circumstances that could confuse the results of the study or interfere with the
             patient's participation throughout the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loreto Gesualdo, MD Full Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology, Dialysis and Transplantation Unit &quot;Aldo Moro&quot; University of Bari</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loreto Gesualdo, MD Full Prof</last_name>
    <phone>+39 080 559</phone>
    <phone_ext>4041</phone_ext>
    <email>loreto.gesualdo@uniba.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOUConsorziale Policlinico Di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uremic toxins</keyword>
  <keyword>gut microbiota dysbiosis</keyword>
  <keyword>sarcopenia</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

